POZEN Logo
Print Page   Close Window

Archives

DATETITLE 
November 24, 2003POZEN Names Dr. James Alexander Senior Vice President, Product DevelopmentPrinter Friendly Version
November 04, 2003POZEN CEO To Present at The CIBC World Markets 14th Annual Healthcare ConferencePrinter Friendly Version
October 30, 2003POZEN Reports Third Quarter 2003 Results; POZEN Reports Revenue for the First Time in Company HistoryPrinter Friendly Version
October 24, 2003POZEN Announces October 30 Webcast of Third-Quarter ResultsPrinter Friendly Version
October 20, 2003POZEN and Xcel Announce Receipt of Not-Approvable Letter for MT 300; Pozen Reports MT 100 Regulatory DevelopmentsPrinter Friendly Version
October 07, 2003POZEN'S New Drug Application for MT 100 for the Treatment of Migraine Accepted for Filing by FDAPrinter Friendly Version
September 24, 2003Results from POZEN Phase IIIb Study Show Early Treatment with MT 100 Improves Efficacy; The Rate of Sustained Pain Relief for Migraine Patients in Study Nears 50%Printer Friendly Version
September 16, 2003POZEN Presents Data Demonstrating That a Two Tablet Dose of MT 100 Appears More Effective Than Imitrex 50 mg in Migraine Patients with Nausea or Severe PainPrinter Friendly Version
September 12, 2003POZEN to Present at Upcoming Investor ConferencesPrinter Friendly Version
September 04, 2003POZEN and Xcel Pharmaceuticals Announce Licensing Agreement to Commercialize Injectable Migraine Treatment MT 300Printer Friendly Version
August 27, 2003POZEN to Present at Upcoming Investor ConferencesPrinter Friendly Version
August 05, 2003POZEN Reports Second Quarter ResultsPrinter Friendly Version
July 31, 2003POZEN Submits New Drug Application to the U.S. FDA for MT 100 for the Acute Treatment of MigrainePrinter Friendly Version
July 30, 2003POZEN Announces August 5 Webcast of Second-Quarter ResultsPrinter Friendly Version
July 22, 2003POZEN and Nycomed Enter into Option Agreement for LornoxicamPrinter Friendly Version
July 16, 2003GlaxoSmithKline and POZEN Migraine Collaboration to Proceed Following Expiration of Hart-Scott-Rodino Waiting PeriodPrinter Friendly Version
July 10, 2003James R. Butler Appointed to POZEN's Board of DirectorsPrinter Friendly Version
July 08, 2003POZEN Receives Expanded Patent Coverage For MT 400 TechnologyPrinter Friendly Version
July 01, 2003POZEN and Nycomed Announce Licensing Agreement to Commercialize Migraine Therapy MT 100 in Nordic CountriesPrinter Friendly Version
June 23, 2003POZEN Presents Phase III Data Demonstrating That MT 300 is Effective in Providing Sustained Pain Relief for the Acute Treatment of MigrainePrinter Friendly Version
June 16, 2003POZEN Announces Upcoming Presentations at the American Headache Society's 45th Annual Scientific MeetingPrinter Friendly Version
June 12, 2003POZEN to Host June 12 Webcast to Discuss Licensing Agreement with GlaxoSmithKline to Develop and Commercialize a Novel Migraine TreatmentPrinter Friendly Version
June 12, 2003GlaxoSmithKline and POZEN Announce Licensing Agreement to Develop and Commercialize a Novel Migraine TreatmentPrinter Friendly Version
May 29, 2003POZEN CEO to Present at the Needham & Company Second Annual Biotechnology ConferencePrinter Friendly Version
May 22, 2003POZEN CEO to Present at Friedman, Billings, Ramsey & Co. Inc., 7th Annual Technology & Growth Investor ConferencePrinter Friendly Version
May 08, 2003POZEN Reports First Quarter Results; Data will be presented at the American Headache Society's 45th Annual Scientific Meeting in JunePrinter Friendly Version
April 30, 2003Pozen Announces May 8 Webcast of First-Quarter ResultsPrinter Friendly Version
April 02, 2003POZEN CEO to Present at the SunTrust Robinson Humphrey 32nd Annual Institutional Investor ConferencePrinter Friendly Version
March 13, 2003POZEN's New Drug Application for MT 300 for the Acute Treatment of Migraine Accepted for Filing by FDAPrinter Friendly Version
February 19, 2003POZEN CEO to Present at the BIO CEO and Investor ConferencePrinter Friendly Version
January 30, 2003POZEN Reports Fourth Quarter and Full-Year 2002 ResultsPrinter Friendly Version
January 24, 2003POZEN Announces Webcast of Fourth Quarter and Full-Year 2002 ResultsPrinter Friendly Version
January 21, 2003POZEN CEO To Present at The U.S Bancorp Piper Jaffray Health Care ConferencePrinter Friendly Version
January 07, 2003POZEN Receives New Patent for MT 300Printer Friendly Version
December 17, 2002POZEN Submits New Drug Application to the U.S. FDA for MT 300 for the Acute Treatment of MigrainePrinter Friendly Version
December 05, 2002Kenneth B. Lee, Jr. Appointed to POZEN'S Board of DirectorsPrinter Friendly Version
November 21, 2002POZEN Receives New Patent for MT 100Printer Friendly Version
October 31, 2002POZEN Reports Third Quarter 2002 ResultsPrinter Friendly Version
October 24, 2002POZEN Announces Plans to Webcast Third-Quarter Earnings Conference CallPrinter Friendly Version
October 08, 2002POZEN Submits Marketing Authorization Application in the United Kingdom for MT 100; Marketing Applications in Other European Countries to Follow Pending Approval in the U.K.Printer Friendly Version
October 04, 2002POZEN's Second Pivotal Study for MT 300 Hits Primary But Not Secondary EndpointsPrinter Friendly Version
October 01, 2002POZEN CEO To Present At the UBS Warburg Global Life Sciences ConferencePrinter Friendly Version
September 10, 2002POZEN CEO to Present At the Bear Stearns Healthcare ConferencePrinter Friendly Version
September 05, 2002Study Shows POZEN's MT 100 to be Well ToleratedPrinter Friendly Version
August 22, 2002POZEN's MT 100 Provides Significant Pain Relief in Difficult-to-Treat Migraine PatientsPrinter Friendly Version
August 01, 2002POZEN Reports Second Quarter Results; Company Anticipates a Lower Loss for the YearPrinter Friendly Version
August 01, 2002POZEN Reaches Agreement With FDA and MCA On MT 400 Development ProgramPrinter Friendly Version
July 31, 2002Paul Rizzo Appointed to POZEN'S Board of DirectorsPrinter Friendly Version
July 25, 2002POZEN To Receive Expanded Patent Coverage for MT 100; Company Receives Notice of Allowance on New Patent for MT 100Printer Friendly Version
July 24, 2002POZEN Announces Plans to Webcast Second-Quarter Earnings Conference CallPrinter Friendly Version
July 22, 2002POZEN's First Pivotal Study for MT 300 Hits Primary Endpoint; NDA On Track for Q4 SubmissionPrinter Friendly Version
April 25, 2002POZEN First-Quarter Results Meet ExpectationsPrinter Friendly Version
April 18, 2002POZEN Inc. Announces Plans to Webcast First-Quarter Earnings Conference CallPrinter Friendly Version
April 11, 2002POZEN Confirms MT 100 Efficacy Equivalent to Market LeaderPrinter Friendly Version
March 06, 2002POZEN Submits Final MT 100 Mouse Carcinogenicity Study Results to FDAPrinter Friendly Version
February 20, 2002POZEN Inc. Reaches Agreement With FDA to Submit Rat Carcinogenicity Study Results During MT 100 NDA Review PeriodPrinter Friendly Version
February 15, 2002POZEN Inc. CEO to Present at The BIO CEO & Investor ConferencePrinter Friendly Version
February 07, 2002POZEN Inc. Releases Fourth-Quarter and Full-Year Results That Meet ExpectationsPrinter Friendly Version
February 04, 2002POZEN Inc. Announces Plans To Webcast Fourth-Quarter Earnings Conference CallPrinter Friendly Version
January 31, 2002POZEN Inc. Commences Final MT 300 Phase III TrialPrinter Friendly Version
January 29, 2002POZEN Inc. Announces Favorable Preliminary Results for MT 100 Six-Month p53 Mouse Carcinogenicity StudyPrinter Friendly Version
January 24, 2002POZEN Inc. CEO to Present at the U.S. Bancorp Piper Jaffray Health Care ConferencePrinter Friendly Version
October 25, 2001POZEN Inc. Releases Third-Quarter Results; Begins Two Clinical TrialsPrinter Friendly Version
October 19, 2001POZEN Inc. Announces Plans to Webcast Third-Quarter Earnings Conference CallPrinter Friendly Version
September 19, 2001POZEN to Submit MT 100 Mouse Carcinogenicity Study Results to FDA in Q1 2002Printer Friendly Version
July 26, 2001POZEN Inc. Second-Quarter Results Meet ExpectationsPrinter Friendly Version
July 23, 2001POZEN Inc. Announces Plans to Webcast Second-Quarter Earnings Conference CallPrinter Friendly Version
May 21, 2001POZEN Inc. Announces Positive Phase II Results for MT 400Printer Friendly Version
April 30, 2001POZEN Inc. First-Quarter Results Meet Expectations; Initiates Six-Month Mouse Carcinogenicity Study; Announces Positive Results for Mt 400 StudyPrinter Friendly Version
April 26, 2001POZEN Inc. Announces Plans to Webcast First-Quarter Earnings Conference CallPrinter Friendly Version
March 01, 2001POZEN Inc. Reports Fourth-Quarter and Full-Year Results That Meet ExpectationsPrinter Friendly Version
February 23, 2001POZEN Inc. Announces Plans to Webcast Fourth-Quarter and Year-End Earnings Conference CallPrinter Friendly Version
February 21, 2001POZEN'S MT 100 Meets Primary Endpoint in Final Phase III TrialPrinter Friendly Version
January 31, 2001POZEN Inc. CEO to Present at Piper Jaffray Health Care ConferencePrinter Friendly Version
January 26, 2001POZEN Inc. Receives FDA Request for Additional MT 100 Carcinogenicity StudiesPrinter Friendly Version
January 16, 2001POZEN Inc. Elects New ChairmanPrinter Friendly Version
December 05, 2000POZEN, Inc. Invites You to Join Its Virtual CEO Summit WebcastPrinter Friendly Version
November 28, 2000POZEN Inc. Completes MT 100 Phase III Trials in Clinic; MT 400 Phase II Trial BeginsPrinter Friendly Version
November 08, 2000POZEN Inc. Reports Third-Quarter and Nine-Month ResultsPrinter Friendly Version
November 07, 2000POZEN'S Underwriters Exercise OverallotmentPrinter Friendly Version
November 06, 2000POZEN Inc. Announces Plans to Webcast Third-Quarter Earnings Conference CallPrinter Friendly Version
November 22, 1999POZEN Inc. Licenses Compound From RochePrinter Friendly Version